Screening using the prostate-specific antigen (PSA) test followed by a standard biopsy has been found to reduce prostate cancer mortality.1 However, organized screening remains debatable due to the possibility of unnecessary biopsies with associated adverse effects as well as the high possibility of overdiagnosis and overtreatment of clinically insignificant cancers. Here, KLK3 is linked to Familial prostate cancer.